EUVIMEDOdkrijte EUVIMED
Open access · CC BY-NC-ND 4.0

Contact allergy to neomycin in consecutively patch tested Danish eczema patients from 2000 to 2023: A cross‐sectional study

Christoffer Kursawe Larsen iD, Mikkel Bak Jensen iD, Jakob F B Schwensen iD

Contact Dermatitis · 2024

DOI: 10.1111/cod.14653 ↗

At a glance

Journal article in Contact Dermatitis, 2024. Written by Christoffer Kursawe Larsen and 2 co-authors. Institution: National Allergy Research Centre, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark. Major MEDLINE topics: Neomycin, Dermatitis, Allergic Contact, Patch Tests. Cited 6 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Danish Environmental Protection Agency under the Ministry of Environment of Denmark.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Neomycin is an aminoglycoside antibiotic that may cause contact allergy. It was withdrawn as a medicine for human use in Denmark in October 2009 but is still found in some vaccines.

Objectives

To identify time trends in contact allergy to neomycin in the period from 2000 to 2023.

Methods

A cross‐section study of patients ≥18 years consecutively patch‐tested with neomycin sulfate (20% in pet.) at Gentofte Hospital, Denmark, during the period 2000–2023 was conducted.

Results

The overall prevalence of contact allergy to neomycin was 1.4%. The prevalence was significantly lower in the period ‘2010–2023’ (1.2%) than in ‘2000–2009’ (1.8%) ( p < 0.005). Contact allergy to neomycin was significantly positively associated with facial dermatitis and age >40 years, and significantly negatively associated with occupational dermatitis and hand dermatitis. No changes in sex, occupational dermatitis, atopic dermatitis, hand dermatitis, leg dermatitis, facial dermatitis, or age > 40/≤40 (the MOAHLFA‐index) were identified when comparing neomycin contact allergic‐patients in the two periods ‘2010–2023’ and ‘2001–2009’.

Conclusion

Neomycin is a rare cause of contact allergy in Denmark with a significantly lower prevalence following its withdrawal as a medicinal product for human use in Denmark in 2009.

Subjects

MeSH terms (MEDLINE)

NeomycinDermatitis, Allergic ContactPatch TestsHumansDenmarkCross-Sectional StudiesFemaleMaleAdultPrevalenceMiddle AgedAnti-Bacterial AgentsDermatitis, OccupationalFacial DermatosesHand DermatosesYoung AdultAgedEczemaAge FactorsLeg DermatosesAdolescent

Author keywords

European Baseline SeriesMOAHLFAallergicantibioticscontact allergycontact dermatitisdermatologyeczemaneomycinneomycin sulfate

Substances

NeomycinAnti-Bacterial Agents

Authors and institutions

  • National Allergy Research Centre, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark.
  • Faculty of Health Science, Institute of Clinical Medicine, University of Copenhagen, Denmark.
  • Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark.

ORCID profiles: Christoffer Kursawe Larsen, Mikkel Bak Jensen, Jakob F B Schwensen

Funding

  • Danish Environmental Protection Agency under the Ministry of Environment of Denmark

Cite

APA

Kursawe Larsen, C., Jensen, M. B., & Schwensen, J. F. B. (2024). Contact allergy to neomycin in consecutively patch tested Danish eczema patients from 2000 to 2023: A cross‐sectional study. Contact Dermatitis. https://doi.org/10.1111/cod.14653

Vancouver

Kursawe Larsen C, Jensen MB, Schwensen JFB. Contact allergy to neomycin in consecutively patch tested Danish eczema patients from 2000 to 2023: A cross‐sectional study. Contact Dermatitis. 2024. doi:10.1111/cod.14653

BibTeX
@article{KursaweLarsen2024,
  author = {Kursawe Larsen, Christoffer and Jensen, Mikkel Bak and Schwensen, Jakob F B},
  title = {Contact allergy to neomycin in consecutively patch tested Danish eczema patients from 2000 to 2023: A cross‐sectional study},
  journal = {Contact Dermatitis},
  year = {2024},
  doi = {10.1111/cod.14653}
}
Start for free →